Dear Editor： Growing evidence demonstrates that β2-glycoprotein Ⅰ （β2GPI） is the key target for antiphospholipid antibodies which are closely associated with thrombotic events in antiphospholipid syndrome （APS） . Anti-β2GPI/β2GPI complex can bind to the surface membrane ofmonocytes and endothelial cells, promoting tissue factor （TF） activity on these cells, and thus increasing the risk of thrombosis.
